However, PPARG and ESR1, as negative regulators, affect the transcription factor signaling pathway by inhibiting NF-κB [39, 40], and some studies have found to support the potential benefits of PPARG agonists in the treatment of asthma. Here, NFKB1 is linked to asthma.